References
- Attard G, Kitzen J, Blagden S, et al (2007). A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. Br J Cancer, 97, 1338-43. https://doi.org/10.1038/sj.bjc.6604043
- Chao MP, Alizadeh AA, Tang C, et al (2010). Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell, 142, 699-713. https://doi.org/10.1016/j.cell.2010.07.044
- Crescence L, Beraud E, Sbarra V, et al (2012). Targeting a novel onco-glycoprotein antigen at tumoral pancreatic cell surface by mAb16D10 induces cell death. J Immunol, 189, 3386-96. https://doi.org/10.4049/jimmunol.1102647
- de Weers M, Tai YT, van der Veer MS, et al (2011). Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol, 186, 1840-8. https://doi.org/10.4049/jimmunol.1003032
- Estevez LG, Martin M, Alba E, et al (2007). Current controversies in the management of early breast cancer. Clin Transl Oncol, 9, 375-84. https://doi.org/10.1007/s12094-007-0070-z
- Gallamini A, Zaja F, Patti C, et al (2007). Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood, 110, 2316-23. https://doi.org/10.1182/blood-2007-02-074641
- Giansanti V, Torriglia A, Scovassi AI (2011). Conversation between apoptosis and autophagy:"Is it your turn or mine?". Apoptosis, 16, 321-33. https://doi.org/10.1007/s10495-011-0589-x
- Gorter A, Meri S (1999). Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol Today, 20, 576-82. https://doi.org/10.1016/S0167-5699(99)01537-6
- Grillo-Lopez AJ, Hedrick E, Rashford M, et al (2002). Rituximab: ongoing and future clinical development. Paper presented at: Seminars in oncology (Elsevier).
- Hernandez AM, Rodriguez N, Gonzalez JE, et al (2011). Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism. J Immunol, 186, 3735-44. https://doi.org/10.4049/jimmunol.1000609
- Jiang L, Hao JL, Jin ML, et al (2013). Effect of embelin on TRAIL receptor 2 mAb-induced apoptosis of TRAIL-resistant A549 non-small cell lung cancer cells. Asian Pac J Cancer Prev, 14, 6115-20. https://doi.org/10.7314/APJCP.2013.14.10.6115
- Loo D, Pryer N, Young P, et al (2007). The glycotope-specific RAV12 monoclonal antibody induces oncosis in vitro and has antitumor activity against gastrointestinal adenocarcinoma tumor xenografts in vivo. Mol Cancer Ther, 6, 856-65.
- Majno G, Joris I (1995). Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol, 146, 3.
- Maloney D (2003). Rituximab for follicular lymphoma. Curr Hematol Rep, 2, 13.
- Parren PW, van de Winkel JG (2008). An integrated science-based approach to drug development. Curr Opin Immunol, 20, 426-30. https://doi.org/10.1016/j.coi.2008.06.006
- Saltz LB, Meropol NJ, Loehrer PJ, et al (2004). Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol, 22, 1201-8. https://doi.org/10.1200/JCO.2004.10.182
- Scott AM, Wolchok JD, Old LJ (2012). Antibody therapy of cancer. Nat Rev Cancer, 12, 278-87. https://doi.org/10.1038/nrc3236
- Thornberry NA, Lazebnik Y (1998). Caspases: enemies within. Science, 281, 1312-6. https://doi.org/10.1126/science.281.5381.1312
- Tyas L, Brophy VA, Pope A, et al (2000). Rapid caspase-3 activation during apoptosis revealed using fluorescence-resonance energy transfer. EMBO Rep, 1, 266-70. https://doi.org/10.1093/embo-reports/kvd050
- Weiner LM, Murray JC, Shuptrine CW (2012). Antibody-based immunotherapy of cancer. Cell, 148, 1081-4. https://doi.org/10.1016/j.cell.2012.02.034
- Willingham SB, Volkmer JP, Gentles AJ, et al (2012). The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA, 109, 6662-7. https://doi.org/10.1073/pnas.1121623109
- Xu G, Wen X, Hong Y, et al (2011). An anti-transferrin receptor antibody enhanced the growth inhibitory effects of chemotherapeutic drugs on human glioma cells. Int Immunopharmacol, 11, 1844-9. https://doi.org/10.1016/j.intimp.2011.07.014
- Yip YL, Ward RL (2002). Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines. Cancer Immunol Immun, 50, 569-87. https://doi.org/10.1007/s002620100226
- Zhang G, Zhang H, Wang Q, et al (2010). Suppression of human prostate tumor growth by a unique prostate-specific monoclonal antibody F77 targeting a glycolipid marker. Proc Natl Acad Sci USA, 107, 732-7 https://doi.org/10.1073/pnas.0911397107
Cited by
- Preparation and Characterization of Anti-GP73 Monoclonal Antibodies and Development of Double-antibody Sandwich ELISA vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.2043
- EHHM, a novel phenolic natural product from Livistona chinensis, induces autophagy-related apoptosis in hepatocellular carcinoma cells vol.12, pp.5, 2016, https://doi.org/10.3892/ol.2016.5178